NASDAQ:CELC Celcuity - CELC Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Celcuity Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $9.36 -0.04 (-0.43%) (As of 02/3/2023 10:46 AM ET) Add Compare Share Share Today's Range$9.27▼$9.5250-Day Range$7.55▼$14.0152-Week Range$4.81▼$14.40Volume2,677 shsAverage Volume55,782 shsMarket Capitalization$144.71 millionP/E RatioN/ADividend YieldN/APrice Target$20.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Celcuity MarketRank™ ForecastAnalyst RatingN/A0.00 Rating ScoreUpside/Downside112.8% Upside$20.00 Price TargetShort InterestBearish2.19% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$1.50 M Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($1.96) to ($1.98) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.41 out of 5 starsMedical Sector923rd out of 1,030 stocksMedical Laboratories Industry23rd out of 25 stocks 2.0 Analyst's Opinion Price Target Upside/DownsideAccording to analysts' consensus price target of $20.00, Celcuity has a forecasted upside of 112.8% from its current price of $9.40.Amount of Analyst CoverageCelcuity has received no research coverage in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted2.19% of the float of Celcuity has been sold short.Short Interest Ratio / Days to CoverCelcuity has a short interest ratio ("days to cover") of 7.4.Change versus previous monthShort interest in Celcuity has recently increased by 96.03%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCelcuity does not currently pay a dividend.Dividend GrowthCelcuity does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CELC. Previous Next 1.4 News and Social Media Coverage News SentimentCelcuity has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Celcuity this week, compared to 1 article on an average week.MarketBeat FollowsOnly 2 people have added Celcuity to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Celcuity insiders have bought 44,904.41% more of their company's stock than they have sold. Specifically, they have bought $1,499,997.00 in company stock and sold $3,333.00 in company stock.Percentage Held by Insiders32.90% of the stock of Celcuity is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 31.05% of the stock of Celcuity is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Celcuity are expected to decrease in the coming year, from ($1.96) to ($1.98) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Celcuity is -3.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Celcuity is -3.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCelcuity has a P/B Ratio of 2.04. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Celcuity (NASDAQ:CELC) StockCelcuity, Inc. is cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. Its proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.Read More Receive CELC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Celcuity and its competitors with MarketBeat's FREE daily newsletter. Email Address CELC Stock News HeadlinesDecember 15, 2022 | finance.yahoo.comBullish insiders bet US$1.6m on Celcuity Inc. (NASDAQ:CELC)December 12, 2022 | finanznachrichten.deCelcuity Inc.: Celcuity Closes $100 Million Private PlacementFebruary 3, 2023 | Investing Trends (Ad)The Humble Mineral at the Heart of the EV Revolution (Not Lithium)You may know of graphite as what's in the tip of a No. 2 pencil, but it is the key to many forms of renewable energy. Today, this humble mineral is at the epicenter of the electric car revolution. Because what most people don't know is today's EV batteries contain more than 220 pounds of graphite – more than lithium, copper or aluminum!December 12, 2022 | finance.yahoo.comCelcuity Closes $100 Million Private PlacementDecember 9, 2022 | finance.yahoo.comCelcuity Presents Updated Results of Phase 1b Study of Gedatolisib in Patients with Advanced Breast Cancer at the 2022 San Antonio Breast Cancer SymposiumDecember 7, 2022 | finance.yahoo.comCelcuity Announces First Patient Dosed in Phase 3 VIKTORIA-1 Clinical Trial of Gedatolisib for the Treatment of HR+/HER2- Advanced Breast CancerNovember 22, 2022 | finance.yahoo.comCelcuity to Present Additional Data for Gedatolisib at the 2022 San Antonio Breast Cancer SymposiumNovember 14, 2022 | seekingalpha.comCelcuity Inc. (CELC) Q3 2022 Earnings Call TranscriptFebruary 3, 2023 | Investing Trends (Ad)The Humble Mineral at the Heart of the EV Revolution (Not Lithium)You may know of graphite as what's in the tip of a No. 2 pencil, but it is the key to many forms of renewable energy. Today, this humble mineral is at the epicenter of the electric car revolution. Because what most people don't know is today's EV batteries contain more than 220 pounds of graphite – more than lithium, copper or aluminum!November 10, 2022 | finance.yahoo.comCelcuity Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateNovember 10, 2022 | finance.yahoo.comCelcuity to Participate in the 13th Annual Craig-Hallum Alpha Select ConferenceNovember 3, 2022 | finance.yahoo.comCelcuity Inc. Schedules Release of Third Quarter 2022 Financial Results and Webcast/Conference CallOctober 17, 2022 | finance.yahoo.comCelcuity Inc. (CELC)October 10, 2022 | reuters.comCELC.O - Celcuity Inc | Stock Price & Latest News | ReutersSeptember 14, 2022 | benzinga.comCelcuity (NASDAQ:CELC) – Celcuity Appoints Polly Murphy, D.V.M., Ph.D., to Board of Directors - BenzingaSeptember 14, 2022 | finance.yahoo.comCelcuity Appoints Polly Murphy, D.V.M., Ph.D., to Board of DirectorsAugust 22, 2022 | reuters.comCELC.OQ - Celcuity Inc | Stock Price & Latest News | ReutersAugust 17, 2022 | nasdaq.comIs Celcuity (NASDAQ:CELC) Using Debt In A Risky Way? - NasdaqAugust 16, 2022 | finance.yahoo.comWhat Is The Ownership Structure Like For Celcuity Inc. (NASDAQ:CELC)? - Yahoo FinanceAugust 15, 2022 | seekingalpha.comCelcuity Inc. (CELC) CEO Brian Sullivan on Q2 2022 Results - Earnings Call TranscriptAugust 11, 2022 | benzinga.comCelcuity: Q2 Earnings Insights - BenzingaAugust 11, 2022 | seekingalpha.comCelcuity GAAP EPS of -$0.55 (NASDAQ:CELC) - Seeking AlphaAugust 11, 2022 | finance.yahoo.comCelcuity Inc. Reports Second Quarter 2022 Financial Results and Provides Corporate UpdateAugust 4, 2022 | benzinga.comCelcuity Inc. Schedules Release of Second Quarter 2022 Financial Results and Webcast/Conference Call - BenzingaAugust 4, 2022 | finance.yahoo.comCelcuity Inc. Schedules Release of Second Quarter 2022 Financial Results and Webcast/Conference CallAugust 3, 2022 | benzinga.comCelcuity to Participate in the Canaccord Genuity 42nd Annual Growth Conference - BenzingaAugust 3, 2022 | finance.yahoo.comCelcuity to Participate in the Canaccord Genuity 42nd Annual Growth ConferenceSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive CELC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Celcuity and its competitors with MarketBeat's FREE daily newsletter. Email Address CELC Company Calendar Last Earnings11/10/2022Today2/03/2023Next Earnings (Estimated)3/22/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Medical laboratories Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CELC CUSIPN/A CIK1603454 Webwww.celcuity.com Phone(763) 392-0767FaxN/AEmployees39Year FoundedN/APrice Target and Rating Average Stock Price Forecast$20.00 High Stock Price Forecast$20.00 Low Stock Price Forecast$20.00 Forecasted Upside/Downside+113.7%Consensus RatingN/A Rating Score (0-4)0.00 Research Coverage0 Analysts Profitability EPS (Most Recent Fiscal Year)($2.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-29,600,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-62.64% Return on Assets-46.85% Debt Debt-to-Equity Ratio0.34 Current Ratio9.74 Quick Ratio9.74 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.61 per share Price / Book2.03Miscellaneous Outstanding Shares15,460,000Free Float10,374,000Market Cap$144.71 million OptionableNot Optionable Beta0.66 Key ExecutivesBrian F. SullivanChairman & Chief Executive OfficerVicky HahneChief Financial OfficerLance G. LaingSecretary, Director & Chief Science OfficerArthur P. DeCillisChief Medical OfficerSheri SmithHead-Clinical OperationsKey CompetitorsDermTechNASDAQ:DMTKPersonalisNASDAQ:PSNLMDxHealthNASDAQ:MDXHGenetronNASDAQ:GTHBiodesixNASDAQ:BDSXView All CompetitorsInsiders & InstitutionsRichard E BullerSold 300 sharesTotal: $3,333.00 ($11.11/share)Brian F SullivanBought 260,869 shares on 12/9/2022Total: $1.50 M ($5.75/share)Captrust Financial AdvisorsBought 628,189 shares on 11/16/2022Ownership: 4.096%Vanguard Group Inc.Sold 1,000 shares on 11/15/2022Ownership: 2.861%PFM Health Sciences LPBought 140,426 shares on 11/15/2022Ownership: 0.908%View All Insider TransactionsView All Institutional Transactions CELC Stock - Frequently Asked Questions What is Celcuity's stock price forecast for 2023? 0 equities research analysts have issued 1-year target prices for Celcuity's shares. Their CELC share price forecasts range from $20.00 to $20.00. On average, they predict the company's stock price to reach $20.00 in the next twelve months. This suggests a possible upside of 112.8% from the stock's current price. View analysts price targets for CELC or view top-rated stocks among Wall Street analysts. How have CELC shares performed in 2023? Celcuity's stock was trading at $14.01 at the beginning of the year. Since then, CELC shares have decreased by 32.9% and is now trading at $9.40. View the best growth stocks for 2023 here. Are investors shorting Celcuity? Celcuity saw a increase in short interest in the month of January. As of January 15th, there was short interest totaling 202,700 shares, an increase of 96.0% from the December 31st total of 103,400 shares. Based on an average daily trading volume, of 27,400 shares, the days-to-cover ratio is presently 7.4 days. Currently, 2.2% of the company's stock are sold short. View Celcuity's Short Interest. When is Celcuity's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 22nd 2023. View our CELC earnings forecast. How were Celcuity's earnings last quarter? Celcuity Inc. (NASDAQ:CELC) posted its quarterly earnings results on Thursday, November, 10th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by $0.26. What other stocks do shareholders of Celcuity own? Based on aggregate information from My MarketBeat watchlists, some companies that other Celcuity investors own include Bank of Hawaii (BOH), InterDigital (IDCC), STAG Industrial (STAG), Evoke Pharma (EVOK), Amicus Therapeutics (FOLD), Allena Pharmaceuticals (ALNA), Ampio Pharmaceuticals (AMPE), Genocea Biosciences (GNCA), Idera Pharmaceuticals (IDRA) and Ovid Therapeutics (OVID). When did Celcuity IPO? (CELC) raised $18 million in an initial public offering (IPO) on Wednesday, September 20th 2017. The company issued 2,000,000 shares at a price of $8.00-$10.00 per share. Craig-Hallum Capital Group acted as the underwriter for the IPO. What is Celcuity's stock symbol? Celcuity trades on the NASDAQ under the ticker symbol "CELC." Who are Celcuity's major shareholders? Celcuity's stock is owned by a variety of institutional and retail investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Brian F Sullivan, Richard E Buller and Richard Nigon. View institutional ownership trends. How do I buy shares of Celcuity? Shares of CELC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Celcuity's stock price today? One share of CELC stock can currently be purchased for approximately $9.40. How much money does Celcuity make? Celcuity (NASDAQ:CELC) has a market capitalization of $145.32 million. The company earns $-29,600,000.00 in net income (profit) each year or ($2.40) on an earnings per share basis. How can I contact Celcuity? Celcuity's mailing address is 16305 36TH AVENUE NORTH SUITE 100, MINNEAPOLIS MN, 55446. The official website for the company is www.celcuity.com. The company can be reached via phone at (763) 392-0767. This page (NASDAQ:CELC) was last updated on 2/3/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.